NASDAQ: GHRS - GH Research PLC

半年間の収益性: -40.22%
セクタ: Healthcare

プロモーションスケジュール GH Research PLC


会社について

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD.

さらに詳しく
The company also develops GH002, an intravenous mebufotenin product candidate; and GH003, an intranasal mebufotenin product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

EBITDA -0.00031
EV/EBITDA 1.61
IPO date 2021-06-25
ISIN IE000GID8VI0
Industry Biotechnology
P/BV 4.38
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.ghres.com
Цена ао 11.09
Число акций ао 0.05202 млрд
1日あたりの価格変動: -2.47% (7.3)
週ごとの価格変動: +3.94% (6.85)
月ごとの料金変更: -23.28% (9.28)
3ヶ月間の価格変動: +3.49% (6.88)
半年間の価格変動: -40.22% (11.91)
年間の価格変動: +22.76% (5.8)
3年間の価格推移: -70.78% (24.37)
5年間の価格推移: 0% (7.12)
10年間の価格推移: 0% (7.12)
年初からの価格変動: +0.4231% (7.09)

過小評価

名前 意味 学年
P/S 0 0
P/BV 1.3 9
P/E 0 0
EV/EBITDA -5.09 0
合計: 3.38

効率

名前 意味 学年
ROA, % -15.73 0
ROE, % -16.25 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.0084 10
合計: 9.4

成長の衝動

名前 意味 学年
収益性 Revenue, % 0 0
収益性 Ebitda, % 13175.16 10
収益性 EPS, % 6062.78 10
合計: 8

機関 音量 共有, %
BVF Inc. 10400158 19.99
RA Capital Management, L.P. 5587333 10.74
RTW Investments LP 3327129 6.39
FMR, LLC 3136869 6.03
Lynx1 Capital Management Lp 1838617 3.53
VR Adviser, LLC 1318327 2.53
Verition Fund Management, LLC 1162485 2.23
Cormorant Asset Management, LP 593043 1.14
Deep Track Capital, LP 499400 0.96
5AM Venture Management, LLC 404404 0.78

ETF 共有, % 年間の利益率, % 配当金, %
AdvisorShares Psychedelics ETF 4.2406 845.99 0.20
SPDR S&P International Small Cap ETF 0.01104 8.94 3.10348



スーパーバイザー 役職 支払い 生年
Mr. Florian Schonharting M.Sc. (Econ) Co-Founder & Non-Executive Chairman of the Board N/A 1969 (56 年)
Mr. Magnus Halle Co-Founder & MD of Ireland N/A 1997 (28 年)
Ms. Julie Ryan F.C.A. Vice President of Finance N/A 1986 (39 年)
Mr. Aaron Cameron M.B.A. Chief Operating Officer N/A 1985 (40 年)
Dr. Velichka Valcheva M.D. Chief Executive Officer N/A 1975 (50 年)

住所: Ireland, Dublin D RY, Joshua Dawson House - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.ghres.com